JBIO
NASDAQ HealthcareJade Biosciences, Inc. - Common Stock
Biotechnology
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
๐ Market Data
| Price | $20.48 |
|---|---|
| Volume | 1,279,078 |
| Market Cap | 1.25B |
| RSI (14-Day) | 39.7 |
| 200-Day MA | $15.91 |
| 50-Day MA | $20.83 |
| 52-Week High | $28.00 |
| 52-Week Low | $6.67 |
| Forward P/E | -8.98 |
| Price / Book | 3.41 |
๐ฏ Investment Strategy Scores
JBIO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (49/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Over-Hyped (19/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find JBIO in your text
Paste any article, transcript, or post โ the tool will extract JBIO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.